Chandrashekar Shivaram
Manipal Hospital Transfusion Services, Manipal Hospital, Bangalore, Karnataka, India.
Asian J Transfus Sci. 2014 Jan;8(1):35-8. doi: 10.4103/0973-6247.126688.
It is well established that Nucleic acid testing (NAT) reduces window phase of transfusion transmissible infections (TTI) and helps improve blood safety. NAT testing can be done individually or in pools. The objectives of this study were to determine the utility, feasibility and cost effectiveness of an in-house minipool-NAT(MP-NAT).
Blood donors were screened by history, tested by ELISA and sero-negative samples were subjected to an in-house NAT by using reverse transcriptase-polymerase chain reaction (RT-PCR). Testing was done in mini-pools of size eight (8). Positive pools were repeated with individual samples.
During the study period of Oct 2005-Sept 2010 (5 years) all blood donors (n=53729) were screened by ELISA. Of which 469 (0.87%) were positive for HIV-1, HBV or HCV. Sero-negative samples (n=53260) were screened by in-house MP-NAT. HIV-NAT yield was 1/53260 (n=1) and HBV NAT yield (n=2) was 1/26630.
NAT yield was lower than other India studies possibly due to the lower sero-reactivity amongst our donors. Nevertheless it intercepted 9 lives including the components prepared. The in-house assay met our objective of improving blood safety at nominal cost and showed that it is feasible to set up small molecular biology units in medium-large sized blood banks and deliver blood within 24-48 hours. The utility of NAT (NAT yield) will vary based on the donor population, the type of serological test used, the nature of kit employed and the sensitivity of NAT test used. The limitations of our in-house MP-NAT consisted of stringent sample preparation requirements, with labor and time involved. The benefits of our MP-NAT were that it acted as a second level of check for ELISA tests, was relatively inexpensive compared to ID-NAT and did not need sophisticated equipment.
核酸检测(NAT)可缩短输血传播感染(TTI)的窗口期并有助于提高血液安全性,这一点已得到充分证实。NAT检测可以单独进行,也可以采用混合样本检测。本研究的目的是确定内部微型混合样本核酸检测(MP-NAT)的实用性、可行性和成本效益。
通过病史对献血者进行筛查,采用酶联免疫吸附测定(ELISA)进行检测,血清学检测呈阴性的样本使用逆转录聚合酶链反应(RT-PCR)进行内部核酸检测。检测以8人一组的微型混合样本进行。阳性混合样本对单个样本进行复测。
在2005年10月至2010年9月的研究期间(5年),所有献血者(n = 53729)均通过ELISA进行筛查。其中469人(0.87%)HIV-1、HBV或HCV检测呈阳性。血清学检测呈阴性的样本(n = 53260)通过内部MP-NAT进行筛查。HIV核酸检测阳性率为1/53260(n = 1),HBV核酸检测阳性率(n = 2)为1/26630。
核酸检测阳性率低于印度的其他研究,这可能是由于我们的献血者中血清反应性较低。尽管如此,它挽救了包括制备的成分在内的9条生命。内部检测以较低的成本实现了我们提高血液安全性的目标,并表明在大中型血库中建立小型分子生物学单位并在24 - 48小时内提供血液是可行的。核酸检测的实用性(核酸检测阳性率)将因献血人群、所用血清学检测类型、所用试剂盒的性质以及所用核酸检测的灵敏度而有所不同。我们内部MP-NAT的局限性包括严格的样本制备要求,涉及人力和时间。我们MP-NAT的优点是它作为ELISA检测的第二级检查,与个体核酸检测(ID-NAT)相比相对便宜,并且不需要复杂的设备。